Immunomedics Announces U.S. Patents Awarded for CD20 Antibody, Veltuzumab, and Reagents Used in Pretargeted Imaging and Therapies Oct 14, 2008
Antibody-dependent cell-mediated cytotoxicity, apoptosis and growth inhibition are similar between rituximab and veltuzumab. However, veltuzumab has a significantly lower off-rate (increased residence time on lymphoma cells) in all lymphoma cell lines tested, and demonstrates significantly higher complement-dependent cytotoxicity in certain human lymphoma cells in vitro. (Primezone Releases)
Galiximab in combination with rituximab in patients with previously untreated follicular lymphoma Jun 8, 2008
Galiximab is an anti-CD80 monoclonal antibody that has been studied as a single-agent in previously treated FL and in combination with rituximab against relapsed FL. The CD80 molecule is found on the surface of activated macrophages, dendritic cells and cells from various subtypes of NHL. Galiximab's potential mechanisms of action include Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and possible immunomodulatory effects on host effector cells affecting the tumor microenvironment. . (EurekAlert!)
Immunomedics Reports High Anti-Lymphoma Potency With Veltuzumab Jun 2, 2008
Antibody-dependent cell-mediated cytotoxicity, apoptosis and growth inhibition are also similar between the two antibodies. However, veltuzumab has a significantly lower off-rate (increased residence time on lymphoma cells) in all lymphoma cell lines tested, but demonstrates significantly higher complement-dependent cytotoxicity in human Daudi lymphoma cells in vitro. (Primezone Releases)
Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS Apr 16, 2008
"These new insights point out that HuMax-EGFr may employ at least three distinct mechanisms of action leading to inhibition of cancer cell growth. HuMax-EGFr is able to induce potent immune system defense activity known as ADCC, block growth factor binding to EGF receptors, and we now established that HuMax-EGFr inhibits EGFR activation by limiting receptor flexibility. This new data further underlines the potential of HuMax-EGFr for treatment of solid cancers." said Lisa N. Drakeman, Ph. D.,... (PR Newswire)
Genmab Announces HuMax-CD32b Pre-Clinical Program Jan 4, 2008
The lead candidate for HuMax-CD32b was selected from a panel of over 60 antibodies based on its excellent selectivity and binding ability for the CD32b target and potent triggering of the immune system killing mechanism antibody-dependent cellular cytotoxicity (ADCC). The antibody was highly effective in suppressing tumor growth in in vivo mouse tumor models in which tumor growth was monitored by highly sensitive bioluminescence imaging. (PR Newswire)
BioWa and Takeda Announce Licensing of BioWa's POTELLIGENT(R) Technology for Use in Antibody Research and Development May 30, 2007
PRINCETON, N.J. and OSAKA, Japan, May 30 /PRNewswire/ -- BioWa, Inc. (BioWa) and Takeda Pharmaceutical Company Limited (TSE4502, Takeda), announced today that they have entered into an agreement which provides Takeda with access to BioWa's patented POTELLIGENT(R) Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies ... About POTELLIGENT(R) Technology POTELLIGENT(R) Technology improves potency and efficacy of antibody therapeutics, by... (PR Newswire)
ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer Jan 10, 2007
In vitro, ERBITUX can mediate antibody-dependent cellular cytotoxicity (ADCC) against certain human tumor types. While the mechanism of ERBITUX' anti-tumor effect(s) in vivo is unknown, all of these processes may contribute to the overall therapeutic effect of ERBITUX. EGFR is part of a signaling pathway that is linked to the growth and development of many human cancers, including those of the head and neck, colon and rectum. (PR Newswire)
